Home › VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
 

Keywords :   


VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers

2013-06-24 09:13:00| drugdiscoveryonline News Articles

VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target

Tags: deal target candidate licensing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »